Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
CLN-619 is a MICA/B directed humanized IgG1 antibody being studied in a global Phase 1 clinical trial in patients with advanced solid tumors. Initial clinical data from the ongoing trial is on-track to be released mid-2023.
CLN-617 is a cytokine therapy combining IL-2 and IL-12 in a single molecule. An Investigational New Drug Application was recently submitted to the FDA for CLN-617.
CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc., (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that posters of preclinical data highlighting the therapeutic potential of two assets, CLN-619 and CLN-617, will be presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando, Florida, April 14-17, 2023.
Details of the Cullinan Oncology posters at AACR are as follows:
Poster Title: The Structural Basis for Inhibition of MICA Shedding and Anti-Tumor Activity of the Monoclonal Anti-MICA/B Antibody, CLN-619
Poster Title: CLN-617 is a First-in-Class Fusion Protein That Retains IL-2 and IL-12 in the Injected Tumor and Potently Triggers Systemic Anti-Tumor Immunity
“We are proud to present data at this year’s AACR conference for two programs in our diverse and robust pipeline, CLN-619 which is a MICA/B directed IgG1 antibody and CLN-617, an IL-2 and IL-12 cytokine therapy,” said Dr. Patrick Baeuerle, Chief Scientific Officer, Cullinan Oncology. “While distinct programs, each has the potential to be a first- and/or best-in-class therapy across a broad range of solid tumor types. We are excited to present more data on these two programs in poster presentations at AACR 2023 and highlight the strides we are making toward creating new standards of care for patients with cancer.”
The posters will expand on preclinical research that has been conducted for both molecules.
About Cullinan Oncology
Our people possess deep scientific expertise, seek innovation openly, and exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients with cancer. Learn more about our Company at www.cullinanoncology.com, and follow us on LinkedIn and Twitter.
Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; success of our clinical trials and preclinical studies; risks related to our ability to protect and maintain our intellectual property position; risks related to manufacturing, supply, and distribution of our product candidates; risks related to the impact of COVID-19 affecting countries or regions in which we have operations or do business, including potential negative impacts on our employees, customers, supply chain and production as well as global economies and financial markets; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither Cullinan nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made.